Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer
Bayley Matthews, Michelle Wong-Brown, Dongli Liu, Christine Yee, Kristie-Ann Dickson, Jennifer Schneider, Saiful Islam, Richard Head, Jennifer H Martin, Caroline E Ford, Deborah J Marsh, Nikola A Bowden · 2024
Read Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer by Bayley Matthews, Michelle Wong-Brown, Dongli Liu, Christine Yee, Kristie-Ann Dickson, Jennifer Schneider, Saiful Islam, Richard Head, Jennifer H Martin, Caroline E Ford, Deborah J Marsh, Nikola A Bowden (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11719850.txt.
Description
Bayley Matthews and co-authors screen old drugs for PARP binding and land on an HIV drug that kills ovarian cancer cells, in a study from two thousand twenty-four. Computer screening ranked drugs by shape match to PARP binders, then dose and harm filters cut the list. The top pick, efavirenz, moved to cell, gel, and patient organoid tests.
The drug killed high-grade serous ovarian cells across all three test beds. Signs showed blocked PARP, DNA harm, cycle arrest, and cell death switches flipped on. Kill doses sat in a mid range that varied by model. The authors pitch the drug as a candidate for trials. Readers get a reuse path worth clinical checks.
Catalog record
| CREATOR | Bayley Matthews, Michelle Wong-Brown, Dongli Liu, Christine Yee, Kristie-Ann Dickson, Jennifer Schneider, Saiful Islam, Richard Head, Jennifer H Martin, Caroline E Ford, Deborah J Marsh, Nikola A Bowden |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |